Search Science Hub

Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

ADA 2026 5 - 8 June 2026

Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2 results in T2D

Authors :

Pablo Mora¹; ²; Vanita R Aroda³; Marisse Asong⁴; Matthias Blüher⁵; Line Dam Heftdal⁴; Amanda-Louise Fenger Carlander⁴; Louise Nygaard Vilsen⁴; Julio Rosenstock¹

Affiliations

View Details Hide Details

Download .PDF

Talking head video:

Keywords

Congress poster

GLP-1 RA

Disease awareness

PHASE 2 (RCT)